Immune Regulation in Inflammation and Cancer

T cells drive immune activation and promote clearance of infections and cancer. However, their function can provoke autoimmune and allergic inflammation. The immune system therefore employs a variety of suppressive mechanisms, known as immunoregulatory mechanisms, to restrain excessive T cell activation and prevent autoimmune and allergic inflammation. It is now known that such suppressive mechanisms inhibit anti-tumour immunity to drive deleterious immunosuppression in cancer. Immunoregulatory mechanisms therefore function as ‘brakes’ within the immune system and have important consequences in infection, inflammation and cancer.

Our research aims to uncover the molecular and cellular mechanisms underpinning immune regulation and cancer immunosuppression. Fundamental discovery in the field of immunoregulation will pave the way for new therapies aimed at manipulating immune function in patients with autoimmunity and cancer (see Research).

Our laboratory, led by Dr Rahul Roychoudhuri, is located at the University of Cambridge Department of Pathology and works closely with collaborators within both the University and broader Cambridge immunology community. Our work benefits from access to the world-class research facilities of the University of Cambridge.

Publication highlights

(For a full list see Publications)

CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function

There is interest in selectively targeting the suppressive function of Treg cells within tumours. We show that high levels of CCR8 expression distinguish highly suppressive Treg cells within tumours, but that genetic deletion of CCR8 has minimal impact on Treg suppressive function or tumor immunity. These findings suggest that CCR8 is not required for Treg suppression within tumours and that depletion of CCR8+ Treg cells rather than blockade of CCR8 function will enable selective cancer immunotherapy.

Whiteside, et al., Immunology (2021)  [PDF]

A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells

Genetic variations underlying risk of complex immune-mediated diseases are concentrated within the non-coding genome at enhancers. The functions of a vast majority of enhancers are unresolved. Using CRISPR-based mutagenesis of human disease-associated enhancer homologs in mice, we show that a distal enhancer at the human 11q13.5 immune disease risk locus promotes Treg-mediated suppression of colitis by driving expression of the TGF-β docking receptor GARP on Treg cells.

Nasrallah, Imianowski, et al., Nature (2020)  [PDF]

Recommended by F1000; Commentary in Sci Immunol 5,eabe0976

BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression

Treg cells are maintained over long periods of time despite a continuous requirement for their suppressive function. This study established a critical function of quiescent cells in Treg maintenance. The transcription factor BACH2 is critical for Treg cell development. We show that in mature Treg cells, Bach2 is highly expressed in quiescent cells where it binds to enhancers of genes associated with Treg activation and represses their TCR- and AP-1-driven induction. By imposing quiescence in this subset of Treg cells, BACH2 promotes maintenance of Treg responses, and durable immune suppression in cancer.

Grant, Yang et al., J Exp Med (2020)  [PDF]

A human monogenic inflammatory disease caused by loss-of-function mutations in BACH2

This study describes a human monogenic disease resulting from inactivating mutations of BACH2, termed BACH2-related Immunodeficiency and Autoimmunity (BRIDA). Affected patients have lymphocyte-differentiation defects associated with immunodeficiency and inflammation of the intestinal tract and lungs. This work resulted from an international collaboration with clinical and academic researchers in the US and UK.

Afzali et al., Nat Immunol (2017) 18:813-823.  [PDF]

BACH transcription factors in innate and adaptive immunity

Here we review roles of BACH family transcriptional repressors in innate and adaptive immunity. We highlight similarities at a molecular level in the cell-type-specific activities of the BACH factors, proposing that competitive interactions of BACH proteins with transcriptional activators of the bZIP family form a common mechanistic theme underlying their diverse actions.

Igarashi, Kurosaki and Roychoudhuri, Nat Rev Immunol (2017) 17:437-450.  [PDF]

High levels of extracellular potassium in tumours suppress T cell activation

This study revealed that cell death in the tumour microenvironment releases intracellular potassium into the extracellular microenvironment of tumours, causing profound suppression of T cell activation. High extracellular potassium concentrations impair T cell receptor (TCR)-driven Akt-mTOR phosphorylation and effector programmes. Engineering CD8+ T cells to be resistant to high extracellular potassium in tumours improves adoptive immunotherapy.

Eil et al., Nature (2016) 537:539-543.  [PDF]

Oxygen-sensing by T cells promotes cancer metastasis to the lung

The lung is a frequent site of cancer metastasis but whether there is an immunological component to this susceptibility has been unclear. Here, we show that T cell responses to metastasis within the lung are restricted by high oxygen concentrations. The HIF prolyl hydroxylases PHD1, PHD2 and PHD3 mediate sensitivity of T cells to oxygen, which suppresses Th1 responses and promotes iTreg responses within the lung. As a consequence, immunologic permissivity of the lung to cancer metastasis is dependent upon PHD1, PHD2 and PHD3.

Clever et al., Cell (2016) 166:1117-1131  [PDF]

BACH2 functions as an AP-1 repressor in lymphocytes to promote CD8+ T cell memory

This study was the first to define BACH2 key regulator of lymphocyte quiescence. We found that BACH2 restrains effector differentiation to promote differentiation of long-lived memory CD8+ T cells after viral infection. We found that BACH2 binds to enhancers where it engages in steric competition with AP-1 factors, limiting TCR-driven induction of AP-1 target genes to promote memory formation. Subsequent work has shown that BACH2 is expressed in stem-like progenitors within T cell responses to cancer.

Roychoudhuri et al., Nat Immunol (2016) 17:851-860.  [PDF]

Commentary by Sidwell and Kallies (Nat Immunol 17:744-5.

The transcription factor BACH2 promotes tumour immunosuppression through its function in Treg cell development

This study established a role of BACH2 in Treg-mediated tumour immunosuppression. This function is corroborated by results of a large in vivo screen of host restriction factors to tumour metastasis (Van der Weyden et al., Nature 2017) and provides a basis for a CRUK-funded drug development programme with CRUK Therapeutic Discovery Laboratories to identify small molecule inhibitors of the suppressive activity of BACH2.

Roychoudhuri et al., J Clin Invest (2016) 126:599-604.  [PDF]

The transcriptional repressor BACH2 is required for Treg cell development and suppression of lethal inflammation

This study established the critical function of the transcription factor BACH2 in immunological tolerance. We found that BACH2 is required for early Treg cell development and its deletion in mice results in lethal inflammation. The findings contributed to our understanding of why genetic polymorphisms within the BACH2 locus in humans are associated with susceptibility to autoimmune and allergic diseases (reviewed in Igarashi, Kurosaki and Roychoudhuri, Nat Rev Immunol 2017).

Roychoudhuri et al., Nature (2013) 498:506-10.  [PDF]

Recommended by F1000